Abstracts Archive - Page 351 of 2425 - ACR Meeting Abstracts

Abstract Number: 2417 • ACR Convergence 2023
Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, caterina Ricordi⁴, federica Macaluso¹, alberto cavazza⁴, Stefania Croci⁴ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
Abstract Number: 2270 • ACR Convergence 2023
Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study
Shounak Ghosh¹, Rajagopal Sankara Narayanan², Katie Bechman³, Ioannis Parodis⁴, Esha Kadam⁵, Wanruchada Katchamart⁶, Phonpen Akarawatcharangura Goo⁷, Abraham Edgar Gracia-Ramos⁸, Parikshit Sen⁹, Elena Nikiphorou³, Sreoshy Saha¹⁰, Ai Lyn Tan¹¹, Tsvetelina Velikova¹², Marcin Milchert¹³, Johannes Knitza¹⁴, Carlo Caballero¹⁵, Dey Dzifa¹⁶, Hector Chinoy¹⁷, COVAD Study Group¹⁸, Rohit Aggarwal¹⁹, Vikas Agarwal²⁰, Latika Gupta²¹ and Chris Wincup²², ¹CMRI Hospital, Kolkata, India, ²Narayana Medical College, Nellore, India, ³King's College London, London, United Kingdom, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁶Mahidol University, Bangkok, Thailand, ⁷Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ⁸Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ⁹Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹³Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁴Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ¹⁵Universidad del Norte, Barranquilla, Colombia, ¹⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ¹⁷The University of Manchester, Sale, United Kingdom, ¹⁸-, -, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²¹Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²²King's College Hospital, London, United Kingdom
Background/Purpose: The management of SLE relies on regular assessment of disease activity. However, patient perception of disease activity can be highly variable and may be…
Abstract Number: 2256 • ACR Convergence 2023
The Impact of Clinical Trial Metrics in Psoriatic Arthritis
Maxine Yarnall and Kara Murray, Spherix Global Insights, Exton, PA
Background/Purpose: Rheumatologists have access to a plethora of advanced biologic and small molecule agents for the treatment of psoriatic arthritis (PsA). Prior to FDA approval,…
Abstract Number: 2414 • ACR Convergence 2023
Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors
Fernando López¹, Javier Loricera², Ivan Ferraz Amaro³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, Juan I. Villa¹⁰, PALOMA VELA¹¹, Susana Romero Yuste¹², Jose L. Callejas¹³, Eugenio De Miguel¹⁴, Eva Galindez-Agirregoikoa¹⁵, Francisca Sivera¹⁶, Jesús Carlos Fernández López¹⁷, Arturo Llobell¹⁸, Julio Sánchez-Martín¹⁹, Calderon Goercke², Lara Sanchez-Bilbao²⁰, Jose L. Hernández²¹ and Ricardo Blanco²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Torrelavega, Spain, ¹¹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹²Complexo Hospitalario Universitario, Pontevedra, Spain, ¹³Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁴Hospital Universitario La Paz, Madrid, Spain, ¹⁵Basurto University Hospital, Bilbao, Spain, ¹⁶Elda General University Hospital, Elda, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸Parc Tauli University Hospital, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ²⁰Hospital Universitario Marques de Valdecilla, Santander, Spain, ²¹Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trial with TCZ in GCA was performed with intravenous (iv)…
Abstract Number: 2395 • ACR Convergence 2023
Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Kresten Keller¹, Chetan Mukhtyar², Andreas Wiggers Nielsen³, Andrea Hemmig⁴, Sarah Mackie⁵, Sebastian Sattui⁶, Ellen Margrethe Hauge³, Anisha Dua⁷, Toby Helliwell⁸, Lorna Neil⁹, Daniel Blockmans¹⁰, Valerie Devauchelle¹¹, eric Hayes³, Annett Jansen Venneboer¹², Sara Monti¹³, Cristina Ponte¹⁴, Eugenio De Miguel¹⁵, Mark Matza¹⁶, Kenneth Warrington¹⁷, Kevin Byram¹⁸, Kinanah Yaseen¹⁹, Christine Peoples²⁰, Mike Putman²¹, Lindsay Lally²², Michael Finikiotis²⁰, Simone Appenzeller²³, Ugo Carmori²³, CARLOS ENRIQUE TORO GUTIERREZ²⁴, Elisabeth Backhouse²⁵, Maria Camila Guerrero²⁶, Victor Pimentel-Quiroz²⁷, Helen Keen²⁵, Claire Owen²⁸, Thomas Daikeler²⁹, Annette De Thurah³, Wolfgang Schmidt³⁰, Elisabeth Brouwer¹² and Christian Dejaco³¹, ¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴University of Basel, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Northwestern University, Chicago, IL, ⁸Keele University, Keele, United Kingdom, ⁹Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Perth, United Kingdom, ¹⁰Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹¹UBO, Brest, France, ¹²University Medical Center Groningen, Groningen, Netherlands, ¹³Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ¹⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶Massachusetts General Hospital, Newton, MA, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸Vanderbilt University Medical Center, Nashville, TN, ¹⁹Cleveland Clinic, Cleveland, OH, ²⁰University of Pittsburgh Medical Center, Pittsburgh, PA, ²¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²²Hospital for Special Surgery, New York, NY, ²³UNICAMP, Campinas, Brazil, ²⁴Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ²⁵University of Western Australia, Daglish, Australia, ²⁶General practice, Cali, Colombia, ²⁷Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ²⁸Austin Health, Malvern East, Australia, ²⁹Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ³⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Existing EULAR/ACR guidelines on polymyalgia rheumatica (PMR) are focused on the management by rheumatologists. However, there is no consensus regarding early referral and evaluation…
Abstract Number: 2422 • ACR Convergence 2023
Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial)
Lisa Christ¹, Harald Bonel², Jennifer Cullmann³, Luca Seitz⁴, Lukas Butikofer⁵, Franca Wagner⁶ and Peter Villiger⁷, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²Department of Diagnostic, Interventional and Pediatric Radiology (DIPR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Campusradiologie, Lindenhofspital Bern, Bern, Switzerland, ³Campusradiologie, Lindenhofspital Bern, Bern, Switzerland, ⁴Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ⁵CTU Bern, University of Bern, Bern, Switzerland, Bern, Switzerland, ⁶University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland, ⁷Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Magnetic resonance imaging (MRI) is well established for diagnosing giant cell arteritis (GCA). Its role in monitoring disease activity has yet to be determined.…
Abstract Number: 2421 • ACR Convergence 2023
Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis
Hussein Baalbaki¹, David Dube¹, Carolyn Ross², Stephanie Ducharme-Benard³, Samer Hussein⁴, Rosalie-Selene Meunier⁴, Christian Pagnoux⁵ and Jean-Paul Makhzoum², ¹Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Confirming the diagnosis of giant cell arteritis (GCA) remains challenging. Available diagnostic tests have limited accuracy and availability. Recently, optic nerve sheath enhancement on…
Abstract Number: 2416 • ACR Convergence 2023
Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study
LUIGI BOIARDI¹, PIERLUIGI MACCHIONI², Francesco Muratore³, Elena Galli⁴, chiara marvisi⁴, Giulia Besutti¹, Lucia Spaggiari¹, Annibale Versari¹ and Carlo Salvarani⁵, ¹IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: No previous study has compared clinical, laboratory and imaging features of relapses in Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA). The aim…
Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Chenyao Wang², Ryu Watanabe³, Hui Zhang³, Mitsuhiro Akiyama³, Kenneth Warrington⁴, Gerald J. Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
Abstract Number: 2415 • ACR Convergence 2023
Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Artem Minalyan¹, Christopher Hino¹, Emily He¹, Osahon Idolor², Chinenye Osuorji³, Nneka Chukwu⁴, Ehizogie Edigin¹ and Vaneet Sandhu⁵, ¹Loma Linda University Health, Loma Linda, CA, ²Piedmont Athens Regional Hospital, Atlanta, GA, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁴Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁵Loma Linda University, Loma Linda, CA
Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…
Abstract Number: 2266 • ACR Convergence 2023
Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception
May Choi¹, Karen Costenbader², Marvin Fritzler¹, Yvan St. Pierre³, Murray Urowitz⁴, John G. Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky³, Daniel Wallace¹⁰, David Isenberg¹¹, Anisur Rahman¹², Joan Merrill¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Ian Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jonsen²², Graciela S Alarcón²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan MacKay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane L. Kamen³², Anca Askanase³³, Jill Buyon³⁴ and Ann Clarke³⁵, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²²Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²³Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, ²⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, Barakaldo, Spain, ²⁷Emory University, Atlanta, GA, ²⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²⁹University of California San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴NYU Grossman School of Medicine, New York, NY, ³⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Using machine learning, we identified 4 patient clusters based on longitudinal autoantibody profiles in an international SLE inception cohort, which were predictive of disease…
Abstract Number: 2280 • ACR Convergence 2023
The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz², Cristina Reategui-Sokolova³, Claudia Elera-Fitzcarrald⁴, Erika Noriega⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinican-reported outcome (ClinRO) correlates well with other disease activity indices such us…
Abstract Number: 2401 • ACR Convergence 2023
A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Colm Kirby¹, Sharon Cowley², Rachael Flood¹, Ronan Mullan¹, Grainne Murphy³ and David Kane⁴, ¹Tallaght University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Cork University Hospital, Cork, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) incorporating Axillary Artery US (AAUS) has become a reliable alternative to biopsy for diagnosing GCA but studies…
Abstract Number: 2408 • ACR Convergence 2023
The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts
Eloise Norman¹, Clare Fraser², Mitchell Lawlor³ and Anthony Sammel⁴, ¹Prince of Wales Hospital, Randwick, Australia, ²Save Sight Institute, The University of Sydney, Sydney, Australia, ³Sydney and Sydney Eye Hospital, Sydney, Australia, ⁴The Prince of Wales Hospital, Sydney, Australia
Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
Abstract Number: 2429 • ACR Convergence 2023
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Chi Chiu Mok¹, SAU MEI TSE², Kar Li Kelly Chan³ and Wai Han Ma¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Shatin, China
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].